(Q36962261)

17 August 2017

1 reference

title

Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. (English)

1 reference

17 August 2017

0 references

Farhan Ali

1

1 reference

17 August 2017

M Adnan Raufi

series ordinal

2

1 reference

17 August 2017

Barbara Washington

series ordinal

3

1 reference

17 August 2017

Jalal K Ghali

series ordinal

4

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Cardiovascular Drug Reviews

17 August 2017

published in

1 reference

17 August 2017

volume

25

1 reference

17 August 2017

issue

3

1 reference

17 August 2017

page(s)

261-279

1 reference

Therapeutic potential of vasopressin receptor antagonists.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

The syndrome of inappropriate secretion of antidiuretic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Diuretic use, progressive heart failure, and death in patients in the DIG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Pancreatic vasopressin V1breceptors: characterization in In-R1-G9 cells and localization in human pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Hemodynamic effects of infused arginine vasopressin in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Vasopressin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Extrapituitary expression of the rat V1b vasopressin receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Two possible actions for circulating angiotensin II in the control of vasopressin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Edema and principles of diuretic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic/endoplasmic reticulum Ca2+ stores

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

The central vasopressinergic system: examining the opportunities for psychiatric drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3466.2007.00019.X

10.1111/J.1527-3466.2007.00019.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference